FITZROY

October 3, 2016

Key Findings on Filgotinib Trial for Crohn’s to be Presented at UEG Week

News

Galapagos will present endoscopic improvements and other key findings from the FITZROY Phase 2 clinical trial of filgotinib in Crohn’s disease, during United European Gastroenterology Week (UEG Week), Oct. 15-19, in Vienna. ... Read more

April 28, 2016April 28, 2016

New Clinical Trial Data on Crohn’s Disease Treatment Filgotinib Reported by Galapagos

News

Beglium-based Galapagos NV recently reported additional data from its Phase 2 FITZROY clinical trial assessing filgotinib, a selective JAK1 inhibitor being investigated for the treatment of Crohn’s disease. The FITZROY trial assessed the efficacy and ... Read more

March 18, 2016March 18, 2016

Galapagos Reports Positive Phase 2 Trial Data of Crohn’s Disease Drug Filgotinib at ECCO Congress

Crohn's Disease, News

Galapagos recently presented data from the FITZROY Phase 2 clinical trial of filgotinib for Crohn’s disease at the 11th ECCO Congress in Amsterdam. Prof. Séverine Vermeire, lead investigator of the trial, presented ... Read more

August 7, 2015August 7, 2015

Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib

Crohn's Disease, News

Galapagos NV a clinical-stage biotechnology company specializing in the discovery and development of small molecule medicines with novel modes of action, recently announced the last patient randomisation in their Phase ... Read more